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During pregnancy, immune cells infiltrate the placenta at different stages of fetal development. NK cells and macrophages are the most predominant cell types. These immune
cells play pleiotropic roles, as they control spiral artery remodeling to ensure appropriate
blood supply and maintain long-term tolerance to a true allograft; yet, they must be
able to mount appropriate immune defenses to pathogens that may threaten the fetus.
Whether the same cell type accomplishes all these tasks or if there are dedicated subsets remains controversial. Here, we identify and characterize two distinct subsets of
myeloid cells that differ in their pro-inflammatory/regulatory capacity. While one subset
predominantly produces the immune-modulating cytokine IL-10, the second subset has
superior capacity to secrete pro-inflammatory mediators, such as IL-1β and IL-6. The
putative regulatory myeloid cells also express high levels of inhibitory receptors and their
ligands, including programmed cell death 1 (PD1) ligands. Importantly, a large fraction of
CD8 and CD4 cells in normal term human placenta are PD1 positive, suggesting that the
PD1/PD1 ligands axis might be critical to maintain tolerance during pregnancy.
Keywords: placenta, antigen-presenting cells, inflammation, tolerance, pregnancy

INTRODUCTION
Pregnancy is a unique situation during which a truly hemi-allogeneic tissue is well protected from
the attack of immune cells that would otherwise have the task of defending “self ” from “foreign.” Still,
maternal cells must be capable of mounting some protective response against bacteria or pathogens
that may harm the fetus (1). Therefore, there must be mechanisms in place that tightly regulate the
immune landscape and compromise tolerance with defense during pregnancy (2).
The placenta is heavily infiltrated from immune cells throughout pregnancy (3, 4). The two most
prominent cell types in the placenta are NK cells and macrophages, both of which exert distinct and
cooperative functions. Collectively, they are involved in trophoblast invasion, spiral artery remodeling
and angiogenesis, removal of apoptotic cells, and protection of the implant from infections (3, 5).
To understand how tolerance is enforced in human placenta, we evaluated dendritic cell (DC)
representation in this tissue, as DCs are key to maintain peripheral tolerance (6). Surprisingly, we
found very few DCs in the basal plate (BP) of normal term human placenta. We instead directed our
attention to a subset of CD14+ MHC classIIhigh myeloid cells, most likely macrophages, that based
on functional studies and unbiased gene array profiling appear to have tolerogenic and regulatory
properties.
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MATERIALS AND METHODS

Histology

Formalin-fixed paraffin-embedded tissue blocks used for this
study were retrieved from the tissue bank of the Department of
Pathology (ASST-Spedali Civili di Brescia, Brescia, Italy). Tissues
used for the analysis included normal placental tissue at the first
(five cases) and third (ten cases) trimester. Four-micron-thick
tissue sections were used for immunohistochemical staining.
Primary antibodies included anti-CD14 (1:50, mouse, clone 7,
Leica); anti-CD163 (1:50, mouse, clone 10D6, Neomarkers);
and anti-HLA-DP,DQ,DR(1:500, mouse, clone CR3/43, DAKO).
The reaction was revealed using Novolink Polymer (Leica
Microsystems) followed by DAB. Microphtalmia-associated
transcription factor (MITF) (1:50, mouse, clone D5, DAKO) was
visualized using Mach 4 MR-AP (Biocare Medical), followed by
Ferangi Blue (Biocare Medical) as chromogen.

Collection of Placental Tissue

This study was carried out in accordance with the recommendations of Washington University School of Medicine IRB
committee with written informed consent from all subjects.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by the
Institutional Review Board of the Washington University School
of Medicine, St. Louis, MO, USA. Placentas were obtained
from singleton, term (37–40 weeks), uncomplicated gestations
delivered by scheduled cesarean section under conduction of
anesthesia without labor or delivered vaginally after spontaneous labor, with delivery in 6 h. Placentas were kept at 4°C until
sampling, with an average time between delivery and sampling of
60 min (range 30–120 min). The placenta was then submitted to
random sampling of the BP (maternal–fetal interface), according
to recommended procedure for placental sample collection (7).
Five to ten en face sections of BP tissue were taken with ~1.5 cm2
surface area and <0.5 cm thickness, avoiding areas of visible
infarcts or calcifications.

GPNMB Staining by Immunofluorescence

Cells were FACS sorted and immobilized on slides by cytospin.
They were then dried overnight and fixed for 15 min in methanol at −20°C. After blocking for 1 h at room temperature with
PBS containing 5% FBS, cells were incubated with biotinylated
anti-GPNMB (R&D) (1:100) overnight at 4°C, followed by 1:200
streptavidin-PE (eBioscience) and DRAQ5 1:500 for DNA staining. Images were obtained at 600X magnification using a Nikon
E800 confocal microscope. Three different placentas were sorted
and cells placed by cytospin on two slides per placenta, and 10
random pictures of each slide were photographed. Intensity of
positive cells for GPNMB per field was quantified using ImageJ
software (NIH), by considering the mean gray value within each
cell, compared to the average background.

Isolation of Cells from the BP, Flow
Cytometry, and Cell Sorting

Basal plate tissue was finely minced with scissors, digested with
collagenase D (1 mg/ml, Roche) for 60 min at 37°C in RPMI
medium with 10% FBS (Hyclone) and pressed through a series of
strainers to yield single cells. For identification of DC populations,
single cells were stained with a combination of lineage markers
(CD3, CD19-PerCP-Cy5.5 eBioscience; CD16, CD56, and CD14PerCP-Cy5.5 Biolegend), CD45-AlexaFluor-700 (Biolegend),
HLA-DR-APC (BD), ILT3-PE-Cy7 (Biolegend), ILT1-PE (eBioscience), CD303-FITC (Miltenyi), and CD1c-Brilliant Violet 510
(Biolegend). Cells were acquired on a LSR-Fortessa (BD) and data
analyzed with the FlowJo software. For FACS sorting experiments
CD14 cells were pre-enriched by magnetic purification (CD14
microbeads, Miltenyi), stained with CD14-FITC (Beckman
Coulter) and HLA-DR-APC (BD), and separated on FACS-AriaII
(BD). For morphological analysis, CD14+MHCIIhigh and CD14+
MHCIIlow cells were immobilized on slides by cytospin and
stained with a Hema 3 stain set. Additional antibodies used for
flow cytometry analysis: immunoglobulin-like transcript (ILT) 2,
CD40, CD54, CD80, CD50, CD89-PE (Beckman Coulter); ILT4APC (eBioscience); ILT5-PE (eBioscience); CXCR4-PE (BD);
CD91-eFluor660 (eBioscience); CD206-Brilliant Violet 421;
CRACC-PE, CD180-PE, CLEC4A-PE (Biolegend); DQ-FITC
(eBioscience); CD9-FITC, CD35-FITC (Beckman Coulter);
IDO-PE (eBioscience); mouse IgG1 Control-PE (eBioscience);
CLEC4A-PE (Biolegend); CD3-Brilliant Violet 605 (Biolegend);
PD1-Brilliant Violet 421 (Biolegend); CD4-APC (eBioscience);
CD8-PerCP-Cy5.5 (Biolegend); CD8-APC (eBioscience); and
CD4-APC-eFluor-780 (eBioscience).

Transcriptome Analysis and Real-time PCR

For gene expression microarrays, RNA from sorted populations
(n = 4 HLA-DRhigh replicates and n = 3 HLA-DRlow replicates)
was prepared using the RNeasy micro kit (Qiagen), following
manufacturer instructions. Gene array data analysis and ingenuity
pathway analysis (IPA) were performed as previously described
(8). The Affymetrix Human Gene (v.1.0) ST array platform was
used (8). Microarrays have been deposited in GEO under accession number GSE104224.
RNA isolation, cDNA generation, and quantitative realtime PCR (qRT-PCR) were done as previously described (9),
except using a total reaction volume per well of 10 µl. To verify
amplification of a single product with the appropriate melting
temperature, dissociation curves were evaluated for all reactions.
RNA expression levels were normalized to parallel reactions with
primers specific for GAPDH. The fold increase gene expression
in experimental relative to control conditions was determined by
utilizing the 2−ΔΔCt method (10).
Primer list: GPNMB 5′-TAAACCTTGAGTGCCTGCGT,
3′-TGAAATCGTTTGG CGGCATC; UBD 5′-TCTCTGGTTT
CTGGCCCCTT, 3′-CGGAACGGACA TGCACACAG; EBI3
5′-AGAGCACATCATCAAGCCCG, 3′-CAGCTCCCTGACGC
TTGTAA; CD80 5′-GGGGAAATGTCGCCTCTCTG, 3′-GTGG
ATTTAGTTTCACAGCTTGC; IDO1 5′-GATGTGGGCTTTG
CTCTACC, 3′-GCTTCCCATTCTCAATCAGC; MITF: 5′-TGT
GACTGAACCAACTGGCACTTAC, 3′-TGCTCCGCCTGCTA

Statistical Analysis

Statistics were calculated as indicated in figure legends using the
Prism7 software.
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CTCGTT; S100A12: 5′-CACTGCTGGCTTTTTGCTGT, 3′-AA
TGCCCCTTCCGAACTGAG; F5: 5′-CACGTGGTTCACTTT
CACGG, 3′-AATGAAC CAGGCAGAAGGGG; and GAPDH: 5′-C
CTGGTATGACAACGAATTT, 3′-AGTGAGGGTCTCTCTCT
TCC.

to exclude T, B, NK, monocytes, and granulocytes, respectively,
and HLA-DR. Among CD45+, Lin-negative HLA-DR+ cells,
we distinguished plasmacytoid DCs (pDCs) and myeloid DCs
(mDCs) based on the expression of ILTs, ILT3 (CD85K, LILRB4)
and ILT1 (CD85H, LILRA2). In blood, ILT3 single positive pDCs
homogenously expressed CD303 (BDCA2), while ILT3/ILT1
double positive cells uniformly expressed CD1c (Figure 1A).
However, in placenta, DC subsets were less prominent than in
blood (Figure 1B). Additionally, the frequency of pDCs and
mDCs among Lin-negative HLA-DR+ cells was significantly lower
in the BP tissue (pDCs: 35.9–10.1%; mDCs: 29.2–2.7%) than in
blood (pDCs: 59.6–30.9%; mDCs: 50.5–30.5%) (Figure 1C).
Frequencies of pDCs and mDCs in placenta were also significantly lower when percentages of the respective DC subsets were
calculated among total CD45+ hematopoietic cells (Figure 1D)
(placenta: pDCs: 0.075–0.015%; mDCs: 0.072–0.039%; blood:
pDCs: 0.35–0.07%; mDCs: 0.18–0.08%).
During these experiments, we noticed a population of Lin+
cells in placenta, which exhibited high expression of HLA-DR
and was poorly represented in blood (Figures 1A,B). We reasoned that high expression levels of MHC class II might be linked
to antigen processing and presentation. Therefore, we further
sought to better characterize this cell subset.

Tissue Culture for Cytokine Quantification

CD14+ HLA-DRhigh and HLA-DRlow cells were plated in identical
numbers (105 cells/well in duplicate) in 200 µl of complete RPMI
medium in wells of a 96 flat bottom plate. Cells were immediately
stimulated with TLR agonists Resiquimod (5 µg/ml; inVivogen);
LPS (100 ng/ml, Ultrapure LPS K12; inVivogen); PolyIC (50 µg/
ml; Amersham), Pam3CSK4 (50 ng/ml; inVivogen), and CpG
1826 (6 µg/ml; Qiagen). Supernatants were collected after 18 h
and cytokines quantified by Cytometric Beads Arrays (Human
Inflammation, BD).

Collection of Term and Pre-Term
Placentas for GPNMB Quantification

A case–control study was also included, under local Ethical
approval. Subjects were enrolled and consented in the Women
and Infant’s Health Specimen Consortium (WHISC). The study
was conducted within the Washington University Medical School
and Barnes Jewish Hospital in Saint Louis, MO, USA from
September 2014 to April 2016. Samples and demographic data
collection were de-identified. Placenta was obtained, as previously described in tissue preparation, from singleton gestation
of normotensive term (≥37–41 weeks) gestations (n = 20), term
pre-eclampsia (n = 20), and pre-term pre-eclampsia with severe
features (≤34 weeks) (n = 16). Pre-eclampsia was diagnosed
as new onset of hypertension and either proteinuria or endorgan dysfunction after 20 weeks of gestation in a previously
normotensive woman (11). Pre-eclampsia with severe features
was defined by the presence of one or more of the following:
unrelieved headache, hepatic abnormality, severe blood pressure
elevation, thrombocytopenia, progressive renal insufficiency,
and pulmonary edema (11). Women with multi-fetal gestations,
known medical conditions, including chronic hypertension,
diabetes mellitus, renal or collagen vascular disease, and fetal
chromosomal abnormalities, were excluded.
Random samples of tissue from the BP were retrieved from
delivered placentas, frozen in liquid nitrogen and stored at
−80°C. RNA was extracted using TRIzol, cDNA prepared from
0.5 µg of total RNA and qRT-PCR carried out as described earlier.

HLA-DRhigh Cells Are a CD14+ Myeloid Cell
Subset That Produces Higher Levels of
IL-10 upon TLR Stimulation than HLADRlow Cells

In the attempt to identify the nature of HLA-DRhigh cells in
placenta, we stained each single lineage marker in combination
with HLA-DR (not shown). HLA-DRhigh cells expressed the lineage marker CD14 (Figure 2A), indicating that they represent a
myeloid/monocytic or macrophagic cell subset. HLA-DRhigh cells
were always less represented than HLA-DRlow cells among CD14+
myeloid cells (average 17.1–41% versus 82.9–56.1%) (Figure 2B).
When we FACS sorted the two subsets to high purity and stained
them with an equivalent of the classical Wright-Giemsa stain,
the morphology of the two subsets was surprisingly similar;
both populations exhibited an indented nucleus and a cytoplasm
containing many vacuoles, most likely corresponding to lipid
droplets (Figure 2C).
Next, we tested the ability of these subsets to respond to TLR
stimulation and to produce cytokines. We found that both subsets
responded to some extent to TLR2, TLR4, and TLR7 stimulations
(Figures 2D,E). However, in general, HLA-DRhigh myeloid cells
produced more IL-10 in response to both LPS and Resiquimod
(Figure 2D), although statistical significance was only reached
for LPS stimulation due to donor variation (Figure S1 in
Supplementary Material). Conversely HLA-DRlow cells produced
significantly more IL-1β and IL-6 in response to LPS (Figure 2D;
Figure S1 in Supplementary Material). Both subsets produced
TNF-α upon TLR4 engagement, and although more donors
yielded higher TNF-α secretion from the HLA-DRlow subset
(Figure 2D), statistical significance was not reached (Figure S1
in Supplementary Material). Neither subset responded vigorously
to TLR3 or TLR9 stimulation (Figure 2E).

RESULTS
DC Subsets in Term Placenta Are Poorly
Represented Compared to Peripheral
Blood

To investigate the nature and abundance of DCs in the BP of normal term human placenta compared to peripheral blood, we took
advantage of our previous staining criteria to identify DC subsets
in circulating blood (12). After collagenase extraction, we stained
placenta cells with a mixture of CD45, to identify hematopoietic
cells, lineage (Lin) markers (CD3, CD19, CD56, CD14, and CD16)
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Figure 1 | Conventional dendritic cell (DC) subsets are poorly represented in basal plate tissue of normal term placentas. (A) Identification of conventional DC
subsets in blood and (B) basal plate tissue of normal term placenta. DC subsets were identified within the Lineage negative HLA-DR+ population as ILT3+ILT1−
plasmacytoid DCs (pDCs), which express BDCA2 (CD303), and as ILT3+ILT1+ myeloid DCs (mDCs), which express CD1c. One representative of eight individual
donors for blood and placenta is shown. (C,D) Percentages of pDCs and mDCs in blood and placenta among lineage negative HLA-DR+ (C) or among total CD45+
(D) cells. Significance was calculated by ordinary one-way ANOVA Tukey’s multiple comparison test. *p < 0.05, **p < 0.005, and ***p < 0.0005.

We conclude that, despite similar morphologies, the two
subsets of myeloid cells identified here are prepared to respond
to pathogens in different ways. HLA-DRlow cells might predominantly recognize Gram negative bacteria that may invade the
placenta and they will produce an inflammatory environment to
curb bacteria spreading. HLA-DRhigh cells may recognize not only
Gram negative bacteria but also ssRNA viruses or, most likely
during uncomplicated normal term pregnancy, circulating fetal
RNAs. By producing higher levels of IL-10 and lower levels of
IL-6 and IL-1β, this cell subset may generate a tolerogenic milieu
that avoids fetal rejection.

significantly differentially expressed greater than two-fold
between subsets (Figure 3A). As a control, we also compared
expression of these genes with expression in a distant cell type,
CD56+ NK cells from human peripheral blood. We identified 287
transcripts that were over-expressed in HLA-DRhigh cells, while
167 were over-expressed in the HLA-DRlow subset. These genes
encode several distinct classes of molecules, including secreted
molecules, pattern recognition receptors (PRRs), transcription
factors (TFs), cell surface receptors, and proteins involved in
cell metabolism or in cell signaling (Figure 3B). Interestingly,
HLA-DRhigh cells expressed elevated levels of many complement
factors, such as C1QA, C1QB, and C1QC, C2 and C3, and CFB,
suggesting that the complement pathway may play a pivotal role
in pregnancy. In addition, they expressed high levels of APOE and
APOC2 and many metabolic genes involved in lipid handling and
modification, such as LPL, SCD, PLTP, FABP5, UGCG, NCEH1,
SGPL1, and LIPA. Moreover, HLA-DRhigh cells expressed EBI3,
also known as p28, a common subunit to the cytokines IL-27
and IL-35, both with known tolerogenic properties. The enzyme
IDO1 was also preferentially expressed on HLA-DRhigh myeloid

Unbiased Gene Expression Profile of the
Placenta Myeloid Subsets Further
Corroborates the Tolerogenic Potential
of HLA-DRhigh Cells

In an attempt to better define the nature of the two myeloid
subsets identified, we analyzed their gene expression signatures
by global gene array profiling. We selected the genes that were
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Figure 2 | CD14+HLA-DRhigh and CD14+HLA-DRlow cells, despite similar morphologies, respond differently to toll-like receptor (TLR) stimulation. (A) Representative
sorting gate to separate CD14+HLA-DRlow and CD14+HLA-DRhigh cells. (B) Relative percentages of HLA-DRhigh to HLA-DRlow after purification with CD14 microbeads
(n = 22). ****p < 0.0001. Significance was calculated by unpaired T-test. (C) Cytospin images of the two myeloid cell subsets. (D) Secretion of IL-1β, IL-6, IL-10,
and TNF-α from HLA-DRlow or HLA-DRhigh cells from different donors (n = 6). A total of 105 cells were either left unstimulated (medium) or stimulated with LPS and
resiquimod and cultured for 18 h prior to cytokine quantifications in supernatants. Each color represents a different donor and assays were run in duplicates. An
arbitrary line was drawn to emphasize enhanced IL-1β and IL-6 secretions by HLA-DRlow, while HLA-DRhigh cells from most donors showed boosted IL-10 secretion.
(E) IL-10 and IL-6 secretions by HLA-DRlow and HLA-DRhigh placental cells in response to different TLR agonists. One representative donor of 2 tested with
PAM3CSK4, PolyI:C, and CpG1826, in addition to LPS and Resiquimod, is shown. An arbitrary line was drawn to emphasize differential cytokine secretion.
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Figure 3 | CD14+HLA-DRlow and HLA-DRhigh have unique transcriptional signatures and differentially express cell surface receptors. (A) Volcano plot representing
transcripts that are significantly and greater than two-fold expressed by HLA-DRlow (n = 3) (red) versus HLA-DRhigh (n = 4) cells (blue). (B) Heatmaps of transcripts
differentially expressed between HLA-DRlow and HLA-DRhigh cells and categorized as secreted proteins, pattern recognition receptors (PRRs), transcription factors
(TFs), cell surface receptors, and molecules involved in metabolism and cell signaling. Transcripts in bold blue (higher expression on HLA-DRhigh) or red (higher
expression in HLA-DRlow) indicate genes, which were subsequently validated by protein expression or RT-PCR. Human peripheral blood NK cells were used as
comparison, with the rationale that having an innate but distant cell type may maximize our ability to identify genes differentially expressed between the two myeloid
cell subsets. (C) Ingenuity pathway analysis networks with highest z-score generated from transcripts differentially expressed between HLA-DRhigh (blue) and
HLA-DRlow (red) cells. (D) Protein expression of costimulatory and antigen presenting molecules and inhibitory receptors of the immunoglobulin-like transcript family
on HLA-DRhigh (blue histograms) as compared to HLA-DRlow (red histograms) cells. (E) Increased protein expression of CD274, IDO, CRACC, and CD9 on
HLA-DRhigh cells and increased expression of CD89, CD35, CD93, and CLEC4A on HLA-DRlow cells. Both subsets express CD206 (mannose receptor) ex vivo.
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cells. This enzyme as well as a second isoform, IDO2, induces
cell tolerance by degrading the essential amino acid tryptophan,
thus limiting proliferation of antigen stimulated T cells (13).
Intriguingly, HLA-DRhigh cells also expressed the TF Blimp-1,
which was shown to promote and sustain the tolerogenic function of DCs in female mice (14).
Consistent with the trend of HLA-DRhigh cells producing
higher levels of IL-10 upon Resiquimod stimulation (Figure S1 in
Supplementary Material), these cells also expressed higher levels
of TLR7. Conversely, HLA-DRlow cells had higher transcripts for
genes involved in inflammation, such as the cytokines IL6, IL8,
and IL1B. PRRs that are involved in recognition of bacterial components and inflammasome activation, such as NOD2 and NLRP3
were also more highly expressed. Noteworthy, only a few genes
over-expressed on one of the two subsets were also expressed at
high levels on peripheral blood NK cells [i.e., CRACC (SLAMF7),
CD62L (SELL), ITGA6, and ICAM3].
Next, we performed IPA on genes with significant differences
greater than two-fold between HLA-DRhigh and HLA-DRlow cells.
This analysis indicated that genes enriched in HLA-DRhigh cells
were linked to LXR/RXR signaling and PPRα/RXRα activation,
nuclear receptors that mostly bind fatty acids or retinoids and
control lipid metabolism. In addition, IPA linked genes enriched
in HLA-DRhigh cells to DC maturation and to the complement
system. On the other hand, genes enriched in HLA-DRlow cells
were connected to IL-6 signaling and to LPS/IL-1- mediated
inhibition of RXR function, which promotes an inflammatory
phenotype in macrophages (Figure 3C).
To functionally validate our data, we selected a few cell surface
receptors for which antibodies were available and measured
expression of these receptors on the two myeloid subsets. As
shown in Figure 3D, costimulatory molecules such as CD40,
CD54, CD80, and CD86, in addition to HLA-DQ, were higher in
HLA-DRhigh cells, in agreement with the DC maturation pathway
identified by our IPA. In addition, several inhibitory receptors

of the ILT family, such as ILT2 (LILRB1), ILT3 (LILRB4), and
ILT4 (LILRB2) had higher expression on HLA-DRhigh, with ILT5
(LILRB3) being an exception, as it was higher on HLA-DRlow
cells. CD274 (PDCD1LG2), a ligand for the inhibitory receptor
programmed cell death 1 (PD1), had also higher expression on
HLA-DRhigh, as did the enzyme IDO. Expression of IDO with
a commercially available antibody was relatively low and an
isotype-matched control was necessary to show a clear shift of
the populations (Figure 2E). HLA-DRhigh cells also expressed
higher level of the CD2 family member CRACC (SLAMF7) (15),
which mediate homotypic interactions and inhibit inflammatory
cytokines in activated monocytes (16). Moreover, they expressed
very high levels of CD9, a tetraspanin induced in human cells by
TGFβ signaling (17), suggesting that HLA-DRhigh cells may reside
in a TGFβ rich environment or develop under the influence of
TGFβ (Figure 3E).
In agreement with our gene array data, HLA-DRlow cells
expressed higher levels of the IgA-specific Fc receptor CD89; the
CR1 CD35; CD93, a receptor which promotes phagocytosis of
apoptotic cells and of antibody and complement opsonized particles; and the lectin CLEC4A, also known as DICR (18), which
binds carbohydrates, including some that decorate pathogens
(19) (Figure 3E). Expression of these receptors supports the idea
that this myeloid subset might be involved in bacterial recognition and removal of immunoglobulin or complement opsonized
pathogens. Notably, CD206, the mannose receptor, was expressed
on both myeloid subsets ex vivo (Figure 3E), suggesting that these
cells are tissue specific and not blood derived monocytes, which
ex vivo are CD206 negative (20).
To localize the two cell types by immunohistochemistry, we
took advantage of our microarray data showing higher expression
of MITF on the HLA-DRhigh subset. MITF is a TF of the MITF/
TFE family involved in lysosomal biogenesis (21). We examined
tissue sections from a set of archival placental tissue from the first
and the third trimesters of gestation. As shown in Figure 4, many

Figure 4 | Tissue histology allows identification of MITF+CD14+ cells in human placenta at different stages of gestation. Sections are from first or third trimester normal
placenta and stained as labeled. CD163+MIFT+ myeloid are found in placental decidua and placental villi (A–D). MIFT+ myeloid cells that co-express CD14 (E–H) and
HLA-DR (I–N) can be identified. Some of these cells are located within small fibrin deposits in the perivillous space (M) and within the decidua (I–L). A variable level of
expression of nuclear MIFT+ is also observed in decidual cells at the 1st trimester (I). Magnification 200× (A–N); scale bare 100 μm. Inserts magnification 600×.
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cells, at both time points, and, in both placental decidua and
villi, stained positive for CD163 and CD14 (Figures 4A–H), two
markers, which selectively identify myeloid cells of the monocyte/
macrophage lineage. Some of these cells showed a clear nuclearassociated staining for MITF (Figures 4B,D,F,H, inserts) and
seemed inter-dispersed among other CD163+ and CD14+ cells
that stained negative for MITF, suggesting that the two myeloid
cell types here identified did not have a distinct localization but
may mingle in the same tissue microenvironment. By double
staining with a MHC-class II-specific antibody, we found MHCclass II+MITF+ cells within small fibrin deposits in the perivillar
space and within the decidua (Figures 4I–N). However, because
of the broad MHC-Class II expression in human on many cell
types, we cannot definitively conclude that those cells represent
our HLA-DRhigh myeloid cells.
To further confirm the differential expression profile of additional genes for which antibodies were not readily available, we
performed real-time PCR experiments. Specifically, we aimed
to validate EBI3, GPNMB, which is a direct downstream target
of MITF (22, 23), UBD, the antimicrobial protein S100A12 (24),
and F5. CD80, IDO, and MITF were included as positive controls.
Indeed, we found that GPNMB, UBD, and EBI3 were expressed
at significantly higher levels in HLA-DRhigh than in HLA-DRlow
cells (Figure 5A). We also tested GPNMB expression by immunofluorescent microscopy at the protein level, as this transcript
was 80-fold more expressed on HLA-DRhigh than on HLA-DRlow.
HLA-DRhigh showed high expression of GPNM throughout the
cytoplasm (Figure 5B), and quantification of the fluorescent
signal by ImageJ analysis in the two populations was statistically
significant (Figure 5C).
We conclude that a substantial portion of the data generated by
our unbiased microarray analysis can be validated at the protein
level and that pathways such as complement, apolipoproteins,
inhibitory receptors/ligands, and immunoregulatory cytokines/
enzymes are a major signature of HLA-DRhigh myeloid cells in the
term human placenta from uncomplicated pregnancies.

Figure 5 | Validation of additional markers on HLA-DRlow and HLA-DRhigh
cells by RT-PCR and at protein level (A–C). (A) Quantitative RT-PCR analysis
of the indicated up- and down-regulated genes in CD14+ MHCIIhigh cells
relative to expression in CD14+ MHCIIlow cells, using GAPDH as a stable
reference gene. Data are shown as mean ± SE, with symbols indicating
results from individual placentas. A letter (i.e., a–c) was included within or next
to the symbol to indicate matching donors. Statistical significance was
determined by Student’s t-test. *p < 0.05 and **p < 0.005. (B) Representative
GPNMB protein expression levels by immunofluorescence in CD14+MHCIIhigh
and MHCIIlow cells. FACS-sorted cells were co-stained for DNA (blue) and
GPNMB (green) and the signal intensity of GPNMB determined using
confocal microscopy. (C) Relative GPNMB signal intensity for the two cell
types (n = 3). Statistical significance was determined by Student’s t-test.
*p < 0.05. (D) Lower expression of GPNMB in placentas from pre-term
preeclamptic pregnancies with severe complications. (D) GPNMB expression
was determined by RT-PCR in basal plate tissue of placentas from women
who had normal term pregnancy (Nterm, n = 20), pre-eclampsia and term
delivery (PEterm, n = 20), and pre-eclampsia with severe complications and
pre-term delivery (PEpre, n = 16). Values were normalized to GAPDH levels.
Statistical significance was determined by ordinary one-way ANOVA.

Decreased GPNMB Expression May
Represent a Prognostic Marker for
Pregnancy-Associated Diseases

A precise function for GPNMB (also known as osteoactivin)
in immune cells has not been reported. However, this protein,
which is also released as soluble form, is highly expressed by some
malignancies, including breast cancers and aggressive melanomas. Anti-GPNMB antibodies are currently in clinical trials
for cancer (25, 26). Because of this link between GPNMB and
cancer (27, 28), we hypothesized that GPNMB could be involved
in maintaining a tolerant environment, which promotes a successful normal term pregnancy. We therefore sought to quantify
GPNMB expression by real-time PCR in term placentas without
pregnancy complications, placentas from term pregnancies
complicated with pre-eclampsia and placentas from pregnancies
with pre-term pre-eclampsia with severe features. As shown in
Figure 5D, we did not observe significant differences between
uncomplicated pregnancies and pregnancies with pre-eclampsia
at term. However, despite large variations among samples, we
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detected a statistically significant difference in GPNMB expression between placentas of term pre-eclampsia and pre-term
pre-eclampsia with severe feature, with the latter group showing
reduced GPNMB expression.
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The PD1/PD ligand 1 (PDL1) Pathway Is
Highly Represented in Normal Term
Placenta

ILT2 was more variable among donors and never as prominent
as PD1 expression.
This findings support the idea that the PD1/PDL1 axis might
limit T-cell expansion driven by fetal alloantigen and may play a
key role in human pregnancy and in establishing tolerance to the
fetal allotransplant.

As PD1 ligands, specifically CD274, had higher expression on
HLA-DRhigh myeloid cells, we hypothesized that this pathway
could contribute to maintenance of tolerance during pregnancy.
We therefore investigated expression of PD1 on T cells in normal term placenta. Interestingly, very high percentages of CD4
(41.5–70%) and CD8 (32.3–79.6%) T cells expressed high levels of
PD1 ex vivo in all the donors tested (Figures 6A,B). To determine
whether placenta T cells exclusively express PD1 or whether they
also express other inhibitory receptors, we investigated expression of ILT2 (CD85J and LILRB1) which binds HLA-G present on
syncytium-trophoblast (29) and also on our myeloid cell subsets
(not shown). We found that a few CD4 (1.7–21%) and some CD8
(9.4–41.8%) expressed ILT2 (Figure 6C). However, expression of

DISCUSSION
In this study, we identified two subsets of CD14+ myeloid cells
that differ in terms of functional responses to TLR stimulation
and cell surface receptors and have a very distinct transcriptional
profile. A seminal study previously described two unique human
decidual populations based on differential expression of CD11c
(30). However, few of the genes identified in our study were also
differentially expressed in those two subsets.

Figure 6 | The inhibitory receptor programmed cell death 1 (PD1) is highly expressed among placental T cells. (A) Expression of PD1 and ILT2 (CD85J) on
placental CD4 and CD8 T cells. Gate was applied on CD19−CD3+ T cells. Four representative donors out of 16 are depicted. (B,C) Percentages of PD1+
(B) and ILT2+ (C) CD4 or CD8 T cells in different donors (n = 16). ****p < 0.0001. Significance was calculated by Student’s t-tests.
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We find that our HLA-DRhigh cells produce more IL-10 and
express higher level of EBI3, a subunit of IL-27 and IL-35, two
members of the IL-12 family of cytokines. Notably, IL-27 and
IL-35 have both immunosuppressive and anti-inflammatory
properties, though by different mechanisms (31–34). IL-27 is
involved in induction of peripheral Foxp3− Tregulatory 1 (Tr1)
T cells, which are immunosupressive through the production of
IL-10 (35–38). IL-35 instead is produced by conventional Foxp3+
Treg, which directly suppresses T-cell proliferation and differentiation (39). B cells can also produce IL-35 (40), which in turn
induces other B cells to produce IL-10 (41, 42). From our data,
it is not clear whether HLA-DRhigh cells produce IL-27 or IL-35.
However, when we looked in placental BP tissue for induced Tr1,
based on expression of CD49b and LAG-3, as previously reported
(43), we did not detect any substantial population of Tr1 among
CD4 T cells. Furthermore, we did not find a significant population of CD4 T cells producing IL-10, when CD4 were maximally
stimulated with PMA and Ionomycin (data not shown).
Interestingly, our HLA-DRhigh myeloid cells expressed many
factors of the complement cascade, as well as APOE and APOC2.
It is well established that during pregnancy there is a systemic
activation of the complement systems (44) and hyperlipoproteinemia. Increase in Apo-CII in serum is documented in late
pregnancy (45). Our data now raise the intriguing possibility
that placenta-associated myeloid cells may be a direct source of
complement factors and apolipropoteins, whose levels increase in
serum during pregnancy.
HLA-DRhigh myeloid cells express PD1 ligands and other
inhibitory receptors, such as ILTs (46). Importantly, PD1 is highly
expressed on a large fraction of CD8 and CD4 cells on all donors
tested, suggesting that the PD1/PD1 ligands’ axis is positioned to
be an important player in establishing and maintaining tolerance
in human pregnancy, similar to the role that PD1/PD1 ligands
play in tumors (47, 48). Accordingly, blockade of PDL1 increases
rejection of allogeneic concepti in mouse models (49). High
expression of ILT2 and ILT4 on HLA-DRhigh cells may also favor
CD8 T cells with a Type-2 cytokine-secreting phenotype (50). In
addition, because ILT2 and ILT4 binds to MHC class I, they might
bind class I molecules in cis and sequester them from binding to
TCR for antigen presentation to CD8 T cells (51).
We show that HLA-DRhigh cells produce GPNMB, a soluble
mediator expressed by highly aggressive tumors and now a
putative target for cancer therapy (28). GPNMB expression on
HLA-DRhigh cells is likely driven by expression of the TF MITF,
given the correlating expression pattern (22, 23). Although we did
not observe any specific effects of soluble GPNMB in inhibiting
proliferation of anti-CD3 stimulated T cells (data not shown), we
cannot exclude that GPNMB has indirect immunosuppressive
function on other cell types that in turn regulate T-cell proliferation and differentiation. We did observe that GPNMB expression
was significantly lower in pre-term pre-eclampsia with severe feature. It has previously been shown that overexpression of GPNMB
results in lower levels of pro-inflammatory cytokines, including
IL-6 and IL-12 (52), which are elevated in pre-eclampsia (53).
In other pathological conditions, such as in acute kidney injury,
GPNMB functions as a negative regulator of inflammation by
promoting IL-10 and TGF-β secretion (54). Therefore, a decrease
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in GPNMB expression in pre-eclampsia with severe features may
represent a sign of worse disease. Alternatively, GPNMB may be
upregulated with pregnancy progression. In the future differentiating between these two hypotheses will be important, as GPNMB
levels in serum of pregnant women may be used as a potential
biomarker to monitor the course and severity of pre-eclampsia.
Despite the fact that our HLA-DRhigh subset bears some features of TGF-β imprinting, such as higher CD9 expression, we
did not observe a specific niche within the decidual tissue or the
villi in which MITF+CD163+CD14+ were preferentially located.
On the contrary, these cells were interspersed with MITF−
CD163+CD14+ cells. This evidence may suggest that either TGF-β
signaling differs between the two subsets or that one subset
may convert to the other under yet unknown circumstances.
Additional studies in animal models will be necessary to dissect
these hypotheses.
In contrast to HLA-DRhigh cells, HLA-DRlow cells seem prepared to mount anti-bacterial response based on their expression of pro-inflammatory factors such as many S100 proteins,
IL-6, IL-1β, NOD2, and NLRP3. Collectively these factors are
well-known drivers of acute inflammation following recognition of bacterial components in part via the inflammasome. This
idea is also supported by greater expression of several endocytic
receptors by HLA-DRlow cells, such as the C-type lectins DCIR,
MCL, and MICL, which may recognize sugar moieties on
pathogens. In addition, these cells express IgA receptors, such
as CD89 and ASGR2, that may bind IgA opsonized bacteria at
the mucosal surfaces. Finally, greater expression of S100A12
by HLA-DRlow cells, confirmed by RT-PCR, supports an antimicrobial role as this protein has large spectrum antibacterial/
antifungal activity due to its zinc binding properties (24, 55).
More in depth analysis and animal models will be required to
further dissect the function of the two myeloid subsets identified
in our study. Nevertheless, our data clearly indicate the existence
of at least two subsets of myeloid cells (monocytes/macrophages)
in the BP of human normal term placentas, which may differ in
their functional properties. One subset seems to exhibit a tolerogenic signature and to utilize immunosuppressive pathways that
are often hijacked by tumors to avoid immune surveillance. The
second subset seems to have more pro-inflammatory and defense
properties and might be involved in protecting the fetus from
exogenous pathogens. Single-cell RNA-seq experiments will also
be required to verify whether diverse cell types are hidden in each
subset, as recently shown for peripheral blood monocytes (56), or
whether they represent homogenous populations with a unique
transcriptional signature.
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